Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease

被引：19
作者：
Patterson, C. E. [2 ]
Todd, S. A. [1 ,2 ]
Passmore, A. P. [1 ,2 ]
机构：
[1] Queens Univ Belfast, Sch Med Dent & Biomed Sci, Ctr Publ Hlth, Belfast BT9 7BL, Antrim, North Ireland
[2] Belfast Hlth & Social Care Trust, Belfast, Antrim, North Ireland
来源：
PHARMACOGENOMICS JOURNAL | 2011年 / 11卷 / 06期
关键词：
Alzheimer's disease; apolipoprotein E; butyrylcholinesterase; cholinesterase inhibitor; E EPSILON-4 ALLELE; MINI-MENTAL-STATE; K-VARIANT; APOE GENOTYPE; TEMPORAL CORTEX; TACRINE THERAPY; ONSET; DONEPEZIL; ASSOCIATION; DEMENTIA;
D O I：
10.1038/tpj.2010.61
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
Factors that influence response to drug treatment are of increasing importance. We report an analysis of genetic factors affecting response to cholinesterase inhibitor therapy in 165 subjects with Alzheimer's disease (AD). The presence of apolipoprotein E epsilon 4 (APOE epsilon 4) allele was associated with early and late cognitive response to cholinesterase inhibitor treatment in mild AD (Mini-Mental State Examination (MMSE) >= 21) (P<0.01). In moderate-to-severe AD (MMSE <= 15), presence of the BCHE-K variant was associated with late response to cholinesterase inhibitor treatment (P = 0.02). Testing for APOE and BCHE genotypes may be useful in therapeutic decision making. The Pharmacogenomics Journal (2011) 11, 444-450; doi:10.1038/tpj.2010.61; published online 20 July 2010
引用
收藏
页码：444 / 450
页数：7
相关论文
共 69 条
  • [1] APOE genotype:: No influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease
    Aerssens, J
    Raeymaekers, P
    Lilienfeld, S
    Geerts, H
    Konings, F
    Parys, W
    [J]. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2001, 12 (02) : 69 - 77
  • [2] Responder characteristics to a single oral dose of cholinesterase inhibitor:: A double-blind placebo-controlled study with tacrine in Alzheimer patients
    Almkvist, O
    Jelic, V
    Amberla, K
    Hellström-Lindahl, E
    Meurling, L
    Nordberg, A
    [J]. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2001, 12 (01) : 22 - 32
  • [3] Alvarez-Arcaya A, 2000, ACTA NEUROL SCAND, V102, P350
  • [4] [Anonymous], 2007, DEMENTIA NICE SCIE G
  • [5] Ballard Clive G., 2005, Current Alzheimer Research, V2, P307
  • [6] BARTELS CF, 1992, AM J HUM GENET, V50, P1086
  • [7] THE CHOLINERGIC HYPOTHESIS OF GERIATRIC MEMORY DYSFUNCTION
    BARTUS, RT
    DEAN, RL
    BEER, B
    LIPPA, AS
    [J]. SCIENCE, 1982, 217 (4558) : 408 - 417
  • [8] Cholinesterase inhibitors for Alzheimer's disease
    Birks, J
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (01):
  • [9] Apolipoprotein E ε4 allele differentiates the clinical response to donepezil in Alzheimer's disease
    Bizzarro, A
    Marra, C
    Acciarri, A
    Valenza, A
    Tiziano, FD
    Brahe, C
    Masullo, C
    [J]. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2005, 20 (04) : 254 - 261
  • [10] Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease
    Blesa, Rafael
    Bullock, Roger
    He, Yunsheng
    Bergman, Howard
    Gambina, Giuseppe
    Meyer, Joanne
    Rapatz, Guenter
    Nagel, Jennifer
    Lane, Roger
    [J]. PHARMACOGENETICS AND GENOMICS, 2006, 16 (11) : 771 - 774
1234567